These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 9751625

  • 21. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM, Schally AV, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 01; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 23. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct 01; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 24. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
    Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G.
    Int J Cancer; 2000 Nov 15; 88(4):652-7. PubMed ID: 11058885
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
    Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G.
    Cancer; 2001 Sep 01; 92(5):1168-76. PubMed ID: 11571730
    [Abstract] [Full Text] [Related]

  • 26. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
    Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G.
    Eur J Cancer; 2001 Mar 01; 37(5):620-8. PubMed ID: 11290438
    [Abstract] [Full Text] [Related]

  • 27. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
    Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S.
    Horm Metab Res; 2010 Oct 01; 42(11):781-6. PubMed ID: 20665426
    [Abstract] [Full Text] [Related]

  • 28. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
    Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, Feil A, Kiaris H, Nagy A.
    Cancer Res; 2002 Feb 01; 62(3):781-8. PubMed ID: 11830533
    [Abstract] [Full Text] [Related]

  • 29. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 01; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 30. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
    Rabbani SA, Harakidas P, Bowlin T, Attardo G.
    Cancer Res; 1998 Aug 01; 58(15):3461-5. PubMed ID: 9699681
    [Abstract] [Full Text] [Related]

  • 31. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
    Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS.
    Urology; 1997 Dec 01; 50(6):999-1006. PubMed ID: 9426741
    [Abstract] [Full Text] [Related]

  • 32. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J, Waser B, Schaer JC, Cescato R, Brazeau JF, Rivier J, Reubi JC.
    J Med Chem; 2003 Dec 18; 46(26):5597-605. PubMed ID: 14667214
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 34. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN, Liebow C.
    Cancer Res; 2000 Aug 01; 60(15):4194-9. PubMed ID: 10945629
    [Abstract] [Full Text] [Related]

  • 35. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.
    Jungwirth A, Schally A, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K, Halmos G.
    Int J Oncol; 1997 May 01; 10(5):877-84. PubMed ID: 21533457
    [Abstract] [Full Text] [Related]

  • 36. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
    Erchegyi J, Penke B, Simon L, Michaelson S, Wenger S, Waser B, Cescato R, Schaer JC, Reubi JC, Rivier J.
    J Med Chem; 2003 Dec 18; 46(26):5587-96. PubMed ID: 14667213
    [Abstract] [Full Text] [Related]

  • 37. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
    Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT.
    Cancer Res; 1992 Jun 01; 52(11):3022-8. PubMed ID: 1591718
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.